OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
KRAS in NSCLC: State of the Art and Future Perspectives
Priscilla Cascetta, Arianna Marinello, Chiara Lazzari, et al.
Cancers (2022) Vol. 14, Iss. 21, pp. 5430-5430
Open Access | Times Cited: 43
Priscilla Cascetta, Arianna Marinello, Chiara Lazzari, et al.
Cancers (2022) Vol. 14, Iss. 21, pp. 5430-5430
Open Access | Times Cited: 43
Showing 1-25 of 43 citing articles:
Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials
Xin Xie, Tingting Yu, Xiang Li, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 144
Xin Xie, Tingting Yu, Xiang Li, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 144
Atherosclerosis Is a Smooth Muscle Cell–Driven Tumor-Like Disease
Huize Pan, Sebastian E. Ho, Chenyi Xue, et al.
Circulation (2024) Vol. 149, Iss. 24, pp. 1885-1898
Open Access | Times Cited: 27
Huize Pan, Sebastian E. Ho, Chenyi Xue, et al.
Circulation (2024) Vol. 149, Iss. 24, pp. 1885-1898
Open Access | Times Cited: 27
Therapeutic advances of targeting receptor tyrosine kinases in cancer
Ciprian Tomuleasa, Adrian Bogdan Țigu, Raluca Munteanu, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 23
Ciprian Tomuleasa, Adrian Bogdan Țigu, Raluca Munteanu, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 23
Impact of KRAS mutation on the tumor microenvironment in colorectal cancer
Yiru Zhou, Yeye Kuang, Chan Wang, et al.
International Journal of Biological Sciences (2024) Vol. 20, Iss. 5, pp. 1947-1964
Open Access | Times Cited: 8
Yiru Zhou, Yeye Kuang, Chan Wang, et al.
International Journal of Biological Sciences (2024) Vol. 20, Iss. 5, pp. 1947-1964
Open Access | Times Cited: 8
Recent advances in the development of inhibitors targeting KRAS-G12C and its related pathways
Dan Zhao, Yu Liu, Fengchao Yi, et al.
European Journal of Medicinal Chemistry (2023) Vol. 259, pp. 115698-115698
Closed Access | Times Cited: 13
Dan Zhao, Yu Liu, Fengchao Yi, et al.
European Journal of Medicinal Chemistry (2023) Vol. 259, pp. 115698-115698
Closed Access | Times Cited: 13
Advancements in NSCLC
Jianan Xu, Lin Tian, Wenlong Qi, et al.
American Journal of Clinical Oncology (2024)
Open Access | Times Cited: 5
Jianan Xu, Lin Tian, Wenlong Qi, et al.
American Journal of Clinical Oncology (2024)
Open Access | Times Cited: 5
Exploring Cellular Plasticity and Resistance Mechanisms in Lung Cancer: Innovations and Emerging Therapies
Caiyu Jiang, Shenglong Xie, Kegang Jia, et al.
Journal of Pharmaceutical Analysis (2025), pp. 101179-101179
Open Access
Caiyu Jiang, Shenglong Xie, Kegang Jia, et al.
Journal of Pharmaceutical Analysis (2025), pp. 101179-101179
Open Access
The continually evolving landscape of novel therapies in oncogene-driven advanced non-small-cell lung cancer
Barbara Melosky, Rosalyn A. Juergens, Shantanu Banerji, et al.
Therapeutic Advances in Medical Oncology (2025) Vol. 17
Open Access
Barbara Melosky, Rosalyn A. Juergens, Shantanu Banerji, et al.
Therapeutic Advances in Medical Oncology (2025) Vol. 17
Open Access
Optimizing Therapeutic Approaches for Aggressive Molecular Subtypes of Metastatic NSCLC
Lukas Delasos
Journal of Thoracic Oncology (2025) Vol. 20, Iss. 1, pp. 23-26
Closed Access
Lukas Delasos
Journal of Thoracic Oncology (2025) Vol. 20, Iss. 1, pp. 23-26
Closed Access
The role of germline and somatic mutations in predicting cancer-associated thrombosis: a narrative review
Vincent Lanting, Marieke J Oskam, Hanneke Wilmink, et al.
Current Opinion in Hematology (2025)
Closed Access
Vincent Lanting, Marieke J Oskam, Hanneke Wilmink, et al.
Current Opinion in Hematology (2025)
Closed Access
Glutamine transporter inhibitor enhances the sensitivity of NSCLC to trametinib through GSDME-dependent pyroptosis
Qingxia Liu, Jinxia Hu, Xuecong Li, et al.
Biochemical Pharmacology (2025) Vol. 233, pp. 116796-116796
Closed Access
Qingxia Liu, Jinxia Hu, Xuecong Li, et al.
Biochemical Pharmacology (2025) Vol. 233, pp. 116796-116796
Closed Access
Current Biomarkers in Non-Small Cell Lung Cancer—The Molecular Pathologist’s Perspective
Konrad Steinestel, Annette Arndt
Diagnostics (2025) Vol. 15, Iss. 5, pp. 631-631
Open Access
Konrad Steinestel, Annette Arndt
Diagnostics (2025) Vol. 15, Iss. 5, pp. 631-631
Open Access
Unravelling key signaling pathways for the therapeutic targeting of non-small cell lung cancer
P. Chavan, Ruchi Pandey, BHEEMANAGOUDA O. PATIL, et al.
European Journal of Pharmacology (2025), pp. 177494-177494
Closed Access
P. Chavan, Ruchi Pandey, BHEEMANAGOUDA O. PATIL, et al.
European Journal of Pharmacology (2025), pp. 177494-177494
Closed Access
Personalized Approaches to Lung Cancer Treatment: A Review of Targeted Therapies, Pharmacogenomics, and Combination Strategies
M. Tabrizi Namini, G. Bhagya, Manjari Sharma
Aspects of Molecular Medicine (2025), pp. 100073-100073
Open Access
M. Tabrizi Namini, G. Bhagya, Manjari Sharma
Aspects of Molecular Medicine (2025), pp. 100073-100073
Open Access
Targeting KRAS-G12C in Lung Cancer: The Emerging Role of PROTACs in Overcoming Resistance
Kumarappan Chidambaram, Arcot Rekha, Ahsas Goyal, et al.
Pathology - Research and Practice (2025), pp. 155954-155954
Closed Access
Kumarappan Chidambaram, Arcot Rekha, Ahsas Goyal, et al.
Pathology - Research and Practice (2025), pp. 155954-155954
Closed Access
Research progress on small molecule inhibitors targeting KRAS G12C with acrylamide structure and the strategies for solving KRAS inhibitor resistance
Zhiyan Jiang, Yan Li, Xin Zhou, et al.
Bioorganic & Medicinal Chemistry (2024) Vol. 100, pp. 117627-117627
Closed Access | Times Cited: 4
Zhiyan Jiang, Yan Li, Xin Zhou, et al.
Bioorganic & Medicinal Chemistry (2024) Vol. 100, pp. 117627-117627
Closed Access | Times Cited: 4
Targeted Therapies for Previously “Undruggable” KRAS-Mutated Non–Small Cell Lung Cancer: A Review of Sotorasib and Adagrasib
Natalie Mausey, Zachery Halford
Annals of Pharmacotherapy (2023) Vol. 58, Iss. 6, pp. 622-635
Closed Access | Times Cited: 10
Natalie Mausey, Zachery Halford
Annals of Pharmacotherapy (2023) Vol. 58, Iss. 6, pp. 622-635
Closed Access | Times Cited: 10
Development of a Scalable Synthesis toward a KRAS G12C Inhibitor Building Block Bearing an All-Carbon Quaternary Stereocenter, Part 1: From Discovery Route to Kilogram-Scale Production
Joyce C. Leung, Yibo Xu, Suttipol Radomkit, et al.
Organic Process Research & Development (2024) Vol. 28, Iss. 1, pp. 67-77
Closed Access | Times Cited: 3
Joyce C. Leung, Yibo Xu, Suttipol Radomkit, et al.
Organic Process Research & Development (2024) Vol. 28, Iss. 1, pp. 67-77
Closed Access | Times Cited: 3
Precision nanomedicine to treat non-small cell lung cancer
Akanksha Dessai, Usha Y. Nayak, Yogendra Nayak
Life Sciences (2024) Vol. 346, pp. 122614-122614
Open Access | Times Cited: 3
Akanksha Dessai, Usha Y. Nayak, Yogendra Nayak
Life Sciences (2024) Vol. 346, pp. 122614-122614
Open Access | Times Cited: 3
A Review of the Molecular Determinants of Therapeutic Response in Non-Small Cell Lung Cancer Brain Metastases
Catherine Boldig, Kimberly Boldig, Sepideh Mokhtari, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 13, pp. 6961-6961
Open Access | Times Cited: 3
Catherine Boldig, Kimberly Boldig, Sepideh Mokhtari, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 13, pp. 6961-6961
Open Access | Times Cited: 3
First Approval of Adagrasib for the Treatment of Non-Small Cell Lung Cancer Harboring a KRASG12C Mutation
Surya K. De
Current Medicinal Chemistry (2023) Vol. 31, Iss. 3, pp. 266-272
Closed Access | Times Cited: 8
Surya K. De
Current Medicinal Chemistry (2023) Vol. 31, Iss. 3, pp. 266-272
Closed Access | Times Cited: 8
Anticancer Effects of 6-Gingerol through Downregulating Iron Transport and PD-L1 Expression in Non-Small Cell Lung Cancer Cells
Dong Young Kang, Sanghyeon Park, Kyoung Seob Song, et al.
Cells (2023) Vol. 12, Iss. 22, pp. 2628-2628
Open Access | Times Cited: 6
Dong Young Kang, Sanghyeon Park, Kyoung Seob Song, et al.
Cells (2023) Vol. 12, Iss. 22, pp. 2628-2628
Open Access | Times Cited: 6
Breaking the ‘Undruggable’ Barrier: Anti-PD-1/PD-L1 Immunotherapy for Non-Small Cell Lung Cancer Patients with KRAS Mutations—A Comprehensive Review and Description of Single Site Experience
Izabela Chmielewska, Paweł Krawczyk, Anna Grenda, et al.
Cancers (2023) Vol. 15, Iss. 14, pp. 3732-3732
Open Access | Times Cited: 5
Izabela Chmielewska, Paweł Krawczyk, Anna Grenda, et al.
Cancers (2023) Vol. 15, Iss. 14, pp. 3732-3732
Open Access | Times Cited: 5
Next Generation Sequencing Analysis and its Benefit for Targeted Therapy of Lung Adenocarcinoma
Vlastimil Kulda, Jiří Polívka, Martin Svatoň, et al.
Cancer Genomics & Proteomics (2023) Vol. 20, Iss. 4, pp. 404-411
Open Access | Times Cited: 4
Vlastimil Kulda, Jiří Polívka, Martin Svatoň, et al.
Cancer Genomics & Proteomics (2023) Vol. 20, Iss. 4, pp. 404-411
Open Access | Times Cited: 4
“Crosstalk between non-coding RNAs and transcription factor LRF in non-small cell lung cancer”
Μάγδα Σπέλλα, Eleftherios Bochalis, Katerina Athanasopoulou, et al.
Non-coding RNA Research (2024) Vol. 9, Iss. 3, pp. 759-771
Open Access | Times Cited: 1
Μάγδα Σπέλλα, Eleftherios Bochalis, Katerina Athanasopoulou, et al.
Non-coding RNA Research (2024) Vol. 9, Iss. 3, pp. 759-771
Open Access | Times Cited: 1
